How to buy Dice Molecules Holdings stock (DICE Therapeutics)

Dice Molecules Holdings is a biotechnology business based in the US. Dice Molecules Holdings shares (DICE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $47.55 – the same closing value as a week prior. Dice Molecules Holdings employs 71 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Dice Molecules Holdings LLC stock

Buy Dice Molecules Holdings stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Dice Molecules Holdings stock price (NASDAQ: DICE)

Use our graph to track the performance of DICE stocks over time.

Dice Molecules Holdings shares at a glance

• Key figures

Information last updated 2023-10-08.

Latest market close	$47.55
52-week range	$0.00 - $0.00
50-day moving average more info button	$45.41
200-day moving average more info button	$34.82
Wall St. target price	$48.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-2.17

Is it a good time to buy Dice Molecules Holdings stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dice Molecules Holdings price performance over time

Historical closes compared with the close of $47.55 from 2023-08-18

1 week (2024-10-19)	N/A
1 month (2024-09-26)	N/A
3 months (2024-07-26)	N/A
6 months (2024-04-26)	N/A

1 year (2023-10-26)	N/A
2 years (2022-10-28)	37.75%
3 years (2021-10-29)	48.13%
5 years (2019-10-26)	N/A

Dice Molecules Holdings financials

Gross profit TTM	$-56,075,000
Return on assets TTM	-14.02%
Return on equity TTM	-21.6%
Profit margin	0%
Book value	$11.89
Market Capitalization more info button	$2.3 billion

TTM: trailing 12 months

Dice Molecules Holdings share dividends

We're not expecting Dice Molecules Holdings to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (5.82% forward annual dividend yield)

Dice Molecules Holdings overview

DICE Therapeutics, Inc. , a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics.

Frequently asked questions

null
What percentage of Dice Molecules Holdings is owned by insiders or institutions?
Currently 3.159% of Dice Molecules Holdings shares are held by insiders and 105.868% by institutions. How many people work for Dice Molecules Holdings?
Latest data suggests 71 work at Dice Molecules Holdings. When does the fiscal year end for Dice Molecules Holdings?
Dice Molecules Holdings's fiscal year ends in December. Where is Dice Molecules Holdings based?
Dice Molecules Holdings's address is: 279 East Grand Avenue, South San Francisco, CA, United States, 94080 What is Dice Molecules Holdings's ISIN number?
Dice Molecules Holdings's international securities identification number is: US23345J1043